

Table S1. Summary of potential drugs and Chinese herbal medicines against viruses

Virus type	Target and Mechanism	Drug Candidate	Potential Natural Compounds
IFV	M2 blocker	Amantadine* ^[1] Rimantadine* ^[1]	Brevilin A ^[2] Aloin ^[4] Phenanthrenes(analogues 4) ^[5] Socorilagin ^[6] Theaflavin-3,3'-DG ^[7]
	NA inhibitor	Oseltamivir* [#] ^[1, 3] Zanamivir* [#] ^[1, 3] Peramivir* [#] ^[1, 3]	Berberine-piperazine derivatives (analoguesBPD-13) ^[8] Pentagalloylglucose ^[2] Kaempferol ^[9] Nepein Hispidulin Rosmarinic acid methylester ^[10] Amurensin K (+)-viniferol C Trans-vitisin B ^[11]
	RdRP inhibitor	Favipiravir Δ ^[12] Ribavirin ^[13] L-742,001 Δ ^[14] S-033188 Δ ^[14] VX-787 Δ ^[14]	/
	HA inhibitor	Nitazoxanide Δ ^[15] DAS181 Δ ^[16]	Oleanane-type triterpenesaponins 7 ^[17] Theaflavin-3,3'-DG ^[7] Pentagalloylglucose ^[2]
	NP inhibitor	Nucleozin ^[12] Naproxen ^[1]	Curcumin ^[1]
	influenza cap-dependent endonuclease inhibitor	Baloxavir marboxil (Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial)	

SARS-CoV-2	3CLpro inhibitor	Kaletra ^[18] Boceprevir ^[19] Nirmatrelvir ^{☆◇[20-22]} Ritonavir ^{☆◇[20-22]}	Quercetin ^[23] Andrographolide ^[24] Baicalin ^[25] Luteolin ^[26] Hesperidin ^[27] Lignan ^[28] Betulinic acid ^[28] Tanshinone ^[28] Cryptotanshinone ^[29] Dihydrotanshinone I ^[29] Tanshinone IIA ^[29] Curcumin ^[28] Shikonin ^[30]
	PLpro inhibitor	Asunaprevir ^[31] Simeprevir ^[32] Vaniprevir/Simeprevir ^[32] Famotidine ^[33] Ebselen ^[34] Disulfiram ^[35] Acriflavine ^[36]	Sodium Tanshinone IIA Sulfonate ^[37] Cryptotanshinone ^[38] Tanshinone I ^[39] Tanshinone IIA ^[40] Dihydrotanshinone I ^[29]
	ACE2 inhibitor	Hydroxychloroquine ^{△[41]} Chloroquine ^{△[41]} Arbidol ^{△[18]} Ribavirin ^{△[41]} Remdesivir ^{△[41]} Favipiravir ^{△[41]}	Emodin ^[42] Glycyrrhizic acid ^[43]
	RdRP inhibitor	Nitazoxanide ^{△[41]} Veklury ^{*◇[44]} Mindvy ^{○[45]}	/
	S protein inhibitor	Arbidol ^{△[41]}	Emodin ^[46] Bis-benzylisoquinoline alkaloids-tetrandrine ^[47]

			Fangchinoline ^[47] Cepharanthine ^[47]
	TMPRSS2 inhibitor	Carmustat mesylate Δ ^[48] Bromhexine hydrochloride ^[49]	/
RSV	RNA transcription inhibitor	Ribavirin* ^[50]	/
	Monoclonal antibody	Palivizumab* ^[51] Motavizumab ^[52]	/
	F protein inhibitor	ViroPharma ^[53] JNJ-53718678 ^[54]	Cleistocaltones A ^[55] Cleistocaltones B ^[55]
	N protein inhibitor	AstraZeneca ^[56]	/
AdV	DNA replication inhibitor	Cidofovir Δ ^[57]	/
		Brincidofovir Δ ^[57]	
		Filiciclovir Δ ^[58]	
		Digoxin ^[57]	
		Digitoxigenin ^[57]	
	Disruptor of HAdV gene expression	Lanatoside C ^[57]	/
		Dexamethasone acetate ^[59]	
		Flunisolide ^[59]	
		Cytarabine ^[59]	
		Niclosamide ^[60]	
Epigenetic regulator-based inhibitor	Oxyclozanide ^[60]	/	
	Rafoxanide ^[60]		
	Gemcitabine ^[61]		
Nuclear transport inhibitor	Chaetocin ^[62]	/	
	Lestaurtinib ^[63]		
Protease/egress Inhibitor	Vorinostat ^[64]	/	
	Ivermectin ^[65]		
		Verdinexor ^[66]	/
		Nelfinavir ^[67]	/

CDK Inhibitor

Flavopiridol^[68]
Roscovitine^[69]

/

*Food and Drug Administration, #Centers for Disease Control and Prevention, Δ clinical trial, \star Emergency Use Authorization, \diamond European Medicine Administration,

\circ National Medical Products Administration

References:

- [1] Han J, Perez J, Schafer A, et al. Influenza virus: Small molecule therapeutics and mechanisms of antiviral resistance. *Curr Med Chem*, 2018, 25: 5115-5127
- [2] Zhang X, Xia Y, Yang L, et al. Brevilin A, a sesquiterpene lactone, inhibits the replication of influenza A virus in vitro and in vivo. *Viruses*, 2019, 11:
- [3] CDC. Influenza antiviral medications: Summary for clinicians. 2017, 2017(
- [4] Huang CT, Hung CY, Hsieh YC, et al. Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza. *Phytomedicine*, 2019, 64: 152904
- [5] Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. *Lancet*, 2017, 390: 946-958
- [6] Chen F, Yang L, Huang Y, et al. Isocorilagin, isolated from *Canarium album* (Lour.) Raeusch, as a potent neuraminidase inhibitor against influenza A virus. *Biochem Biophys Res Commun*, 2020, 523: 183-189
- [7] Zu M, Yang F, Zhou W, et al. In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. *Antiviral Res*, 2012, 94: 217-224
- [8] Enkhtaivan G, Kim DH, Park GS, et al. Berberine-piperazine conjugates as potent influenza neuraminidase blocker. *Int J Biol Macromol*, 2018, 119: 1204-1210
- [9] Jeong HJ, Ryu YB, Park SJ, et al. Neuraminidase inhibitory activities of flavonols isolated from *Rhodiola rosea* roots and their in vitro anti-influenza viral activities. *Bioorg Med Chem*, 2009, 17: 6816-6823
- [10] Bang S, Quy Ha TK, Lee C, et al. Antiviral activities of compounds from aerial parts of *Salvia plebeia* L. *J Ethnopharmacol*, 2016, 192: 398-405
- [11] Nguyen TNA, Dao TT, Tung BT, et al. Influenza A (H1N1) neuraminidase inhibitors from *Vitis amurensis*. *Food Chemistry*, 2011, 124: 437-443
- [12] Yen HL. Current and novel antiviral strategies for influenza infection. *Curr Opin Virol*, 2016, 18: 126-134
- [13] Cheung PP, Watson SJ, Choy KT, et al. Generation and characterization of influenza A viruses with altered polymerase fidelity. *Nat Commun*, 2014, 5: 4794
- [14] Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. *Influenza Other Respir Viruses*, 2017, 11: 240-246
- [15] Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. *Lancet Infect Dis*, 2014, 14: 609-618
- [16] Zenilman JM, Fuchs EJ, Hendrix CW, et al. Phase 1 clinical trials of das181, an inhaled sialidase, in healthy adults. *Antiviral Res*, 2015, 123: 114-119
- [17] Mair CE, Grienke U, Wilhelm A, et al. Anti-influenza triterpene saponins from the bark of *Burkea africana*. *J Nat Prod*, 2018, 81: 515-523
- [18] Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. *Jama*, 2020, 323: 1824-1836
- [19] Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Res*, 2020, 178: 104786
- [20] Administration USFaD. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. 2021, 2021(December 22):
- [21] Pfizer. Paxlovid: EPAR - product information. 2023, 2023(January 8):
- [22] Administration USFaD. Paxlovid (PF-07321334) EUA. 2024, 2024(March 13):
- [23] Wu W, Li R, Li X, et al. Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. *Viruses*, 2015, 8:
- [24] Yu B, Dai CQ, Jiang ZY, et al. Andrographolide as an anti-H1N1 drug and the mechanism related to retinoic acid-inducible gene-1-like receptors signaling pathway. *Chin J Integr Med*, 2014, 20: 540-545
- [25] Su H, Yao S, Zhao W, et al. Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. *bioRxiv*, 2020,
- [26] Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from *Torreya nucifera* displaying SARS-CoV-2 3CL(pro) inhibition. *Bioorg Med Chem*, 2010, 18: 7940-7947
- [27] Lin CW, Tsai FJ, Tsai CH, et al. Anti-SARS coronavirus 3C-like protease effects of *Isatis indigotica* root and plant-derived phenolic compounds. *Antiviral Res*, 2005, 68: 36-42
- [28] Wen CC, Kuo YH, Jan JT, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. *J Med Chem*, 2007, 50: 4087-4095

- [29] Park JY, Kim JH, Kim YM, et al. Tanshinones as selective and slow-binding inhibitors for sars-cov cy steine proteases. *Bioorg Med Chem*, 2012, 20: 5928-5935
- [30] Zhenming Jin , Xiaoyu Du , Yechun Xu , et al. Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting covid-19. *bioRxiv*, 2020,
- [31] Anson BJ, Chapman ME, Lendy EK, et al. Broad-spectrum inhibition of coronavirus main and papain-like proteases by hcv drugs. *Res Square (Preprint)*, 2020,
- [32] Gammeltoft KA, Zhou Y, Duarte Hernandez CR, et al. Hepatitis c virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of sars-cov-2 in vitro. *Antimicrob Agents Chemother*, 2021, 65: e0268020
- [33] Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for sars-cov-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B*, 2020, 10: 766-788
- [34] Weglarz-Tomczak E, Tomczak JM, Talma M, et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from sars-cov-2. *Sci Rep*, 2021, 11: 3640
- [35] Sargsyan K, Lin CC, Chen T, et al. Multi-targeting of functional cysteines in multiple conserved sars-cov-2 domains by clinically safe zn-ejectors. *Chem Sci*, 2020, 11: 9904-9909
- [36] Napolitano V, Dabrowska A, Schorpp K, et al. Acriflavine, a clinically approved drug, inhibits sars-cov-2 and other betacoronaviruses. *Cell Chem Biol*, 2022, 29: 774-784.e778
- [37] Xu Y, Chen K, Pan J, et al. Repurposing clinically approved drugs for covid-19 treatment targeting sars-cov-2 papain-like protease. *Int J Biol Macromol*, 2021, 188: 137-146
- [38] Zhao Y, Du X, Duan Y, et al. High-throughput screening identifies established drugs as sars-cov-2 plp inhibitors. *Protein Cell*, 2021, 12: 877-888
- [39] Lim CT, Tan KW, Wu M, et al. Identifying sars-cov-2 antiviral compounds by screening for small molecule inhibitors of nsp3 papain-like protease. *Biochem J*, 2021, 478: 2517-2531
- [40] Fang ZY, Zhang M, Liu JN, et al. Tanshinone iia: A review of its anticancer effects. *Front Pharmacol*, 2020, 11: 611087
- [41] Zhang Q, Xiang R, Huo S, et al. Molecular mechanism of interaction between sars-cov-2 and host cells and interventional therapy. *Signal Transduct Target Ther*, 2021, 6: 233
- [42] Schwarz S, Wang K, Yu W, et al. Emodin inhibits current through sars-associated coronavirus 3a protein. *Antiviral Res*, 2011, 90: 64-69
- [43] Yu S, Zhu Y, Xu J, et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of sars-cov-2. *Phytomedicine*, 2021, 85: 153364
- [44] Administration USFaD. Fda approves first treatment for covid-19. 2020,
- [45] Biosciences J. Junshi biosciences announces approval for marketing of vv116 in china. 2023, 2023 (January 29):
- [46] Ho TY, Wu SL, Chen JC, et al. Emodin blocks the sars coronavirus spike protein and angiotensin-converting enzyme 2 interaction. *Antiviral Res*, 2007, 74: 92-101
- [47] Kim DE, Min JS, Jang MS, et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus oc43 infection of mrc-5 human lung cells. *Biomolecules*, 2019, 9:
- [48] Hoffmann M, Kleine-Weber H, Schroeder S, et al. Sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. *Cell*, 2020, 181: 271-280.e278
- [49] Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease tmprss2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov*, 2014, 4: 1310-1325
- [50] Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. *Cochrane Database Syst Rev*, 2007, Cd000181
- [51] Alansari K, Toaimah FH, Almatar DH, et al. Monoclonal antibody treatment of rsv bronchiolitis in young infants: A randomized trial. *Pediatrics*, 2019, 143:
- [52] Ramilo O, Lagos R, Sáez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. *Pediatr Infect Dis J*, 2014, 33: 703-709
- [53] Kim YI, Pareek R, Murphy R, et al. The antiviral effects of rsv fusion inhibitor, mdt-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. *Influenza Other Respir Viruses*, 2017, 11: 525-530
- [54] Roymans D, Alnajjar SS, Battles MB, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. *Nat Commun*, 2017, 8: 167
- [55] Song JG, Su JC, Song QY, et al. Cleistocaltones a and b, antiviral phloroglucinol-terpenoid adducts from *Cleistocalyx operculatus*. *Org Lett*, 2019, 21: 9579-9583

- [56] Chapman J, Abbott E, Alber DG, et al. Rsv604, a novel inhibitor of respiratory syncytial virus replication. *Antimicrob Agents Chemother*, 2007, 51: 3346-3353
- [57] Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. *Antimicrob Agents Chemother*, 2005, 49: 1010-1016
- [58] Toth K, Hussein ITM, Tollefson AE, et al. Filociclovir is a potent in vitro and in vivo inhibitor of human adenoviruses. *Antimicrob Agents Chemother*, 2020, 64:
- [59] Saha B, Varette O, Stanford WL, et al. Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. *Virology*, 2019, 538: 24-34
- [60] Marrugal-Lorenzo JA, Serna-Gallego A, Berastegui-Cabrera J, et al. Repositioning salicylanilide antihelminthic drugs to treat adenovirus infections. *Sci Rep*, 2019, 9: 17
- [61] Gray SG, Baird AM, O'Kelly F, et al. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. *Int J Mol Med*, 2012, 30: 1505-1511
- [62] Greiner D, Bonaldi T, Eskeland R, et al. Identification of a specific inhibitor of the histone methyltransferase su(var)3-9. *Nat Chem Biol*, 2005, 1: 143-145
- [63] Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (cep701) is a jak2 inhibitor that suppresses jak2/stat5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. *Blood*, 2008, 111: 5663-5671
- [64] Saha B, Parks RJ. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses human adenovirus gene expression and replication. *J Virol*, 2019, 93:
- [65] Tessier TM, Dodge MJ, Prusinkiewicz MA, et al. Viral appropriation: Laying claim to host nuclear transport machinery. *Cells*, 2019, 8:
- [66] Widman DG, Gornisiewicz S, Shacham S, et al. In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals. *PLoS One*, 2018, 13: e0200043
- [67] Georgi F, Kuttler F, Murer L, et al. A high-content image-based drug screen of clinical compounds against cell transmission of adenovirus. *Sci Data*, 2020, 7: 265
- [68] Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. *Nat Rev Drug Discov*, 2015, 14: 130-146
- [69] Veselý J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. *Eur J Biochem*, 1994, 224: 771-786